Agios Pharmaceuticals, Inc. - Common Stock (AGIO)

$35.19 0.28 (0.79%)

16:00 EST AGIO Stock Quote Delayed 30 Minutes

AGIO Stock Earnings: Agios Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024

By InvestorPlace Earnings May 2, 2024

AGIO stock results show that Agios Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

The 3 Best Biotech Stocks to Buy Now: Q2 Edition

7 Biotech Stocks Fighting America’s Deadliest Diseases

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Volume:

Previous Close -

Market Cap 2.07B

PE Ratio 3.10

EPS 11.34

Volume (Avg. Vol.) 775,603

Day's Range $34.42 - $35.75

52-Week Range $27.14 - $62.58

Dividend & Yield N/A (N/A)

AGIO Stock Predictions, Articles, and Agios Pharmaceuticals, Inc. - Common Stock News

7 Biotech Stocks to Buy for 100% Returns

By Josh Enomoto, InvestorPlace Contributor Apr 9, 2023

If you can handle the risks associated with high volatility, these biotech stocks to buy might double the returns in your portfolio.

7 Biotech Stocks That Could Be the Next Big Thing

By Josh Enomoto, InvestorPlace Contributor Mar 15, 2023

Although speculation might be a tough call at this juncture, these biotech stocks and their underlying science might be compelling enough.

7 Best Biotech Stocks to Buy in 2021 with Huge Upside

By Alex Sirois, InvestorPlace Contributor Aug 25, 2021

Biotech stocks are worth considering. Risk aside, big pharma firms can still produce big pharma returns at the end of the day.

5 Biotech Stocks That Could Face M&A Next!

By Aaron Levitt, InvestorPlace Contributor Jan 10, 2019

Big biotech buyouts have already started happening. These five biotech stocks could be the next to go.

Agios Pharmaceuticals, Inc.Stock Is an Analyst Darling for Good Reason

By Chris Lau, InvestorPlace Contributor Jun 5, 2018

Celgene buying out Agios would make sense but either way the company's work on cellular metabolism and gene deleting is interesting the bulls the most. Agios stock is a good buy on its own merits.

7 ‘Strong Buy’ Stocks With 100% Wall Street Support

By Harriet Lefton, Writer, TipRanks Nov 17, 2017

These seven rare stocks have received only "buy" ratings from Wall Street's best analysts, with more upside predicted to come.

Liberty Sirius XM Group (LSXMK) Lead 12 Activist Investor Reports

By Fintel Apr 25, 2017

Recent 13-D and 13-G filings are windows into activist investors activity. We look at Liberty Sirius XM Group and 11 others

40 Biotechnology Stocks to Sell Now

By Portfolio Grader Dec 12, 2016

This week, the overall grades of 40 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

40 Biotechnology Stocks to Sell Now

By Portfolio Grader Dec 5, 2016

The overall ratings of 40 Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

Why Agios Pharmaceuticals Inc (AGIO), LPL Financial Holdings Inc (LPLA) and Humana Inc (HUM) Are 3 of Today’s Worst Stocks

By James Brumley, InvestorPlace Feature Writer Dec 5, 2016

Agios (AGIO), LPL Financial (LPLA) and Humana (HUM) were wishing the weekend could have lasted one more day on Monday.

Agios Pharmaceuticals, Inc. - Common Stock (AGIO)

AGIO Stock Earnings: Agios Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024

The 3 Best Biotech Stocks to Buy Now: Q2 Edition

7 Biotech Stocks Fighting America’s Deadliest Diseases

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

Agios Pharmaceuticals, Inc. - Common Stock (AGIO)

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

AGIO Stock Predictions, Articles, and Agios Pharmaceuticals, Inc. - Common Stock News

Subscriber Sign in